ENGN today
$1.98+$0.18 (+9.72%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $48.96
Key levels
Resistance$6.05
Resistance$2.02
Support$1.88
Support$1.75
Latest news & SEC filings
ProductenGene Reports New Pivotal Bladder Cancer Data and Names Executives
AnalystPiper Sandler raises enGene Therapeutics to Overweight, keeps $4 target
AnalystWells Fargo raises enGene Therapeutics to Overweight, price target to $6
All ENGN news →About enGene
enGene is a biotech company in the clinic stage that develops gene-based treatments using non-viral delivery. Its main candidate, detalimogene voraplasmid, is under study as a single-agent therapy for bladder cancer that has grown into the inner lining but not the muscle, including cases that stopped responding to BCG. The firm's DDX platform aims to place genetic material at chosen sites, and it also runs early-stage work on other tumor types.
Based on the company's 10-K filed Dec 22, 2025.
Nasdaq · Healthcare
enGene Therapeutics Inc. (ENGN)
What Is the Price Target for ENGN?
SEPT Low Target
$3.40
SEPT Mid Target
$4.00
SEPT High Target
$4.60
Analyst Consensus
$4.00
Is ENGN a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ENGN.
Start Free Trial →Is ENGN Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, PEG, Analyst Consensus
Fair Value
$2.54
15
Moat Score
NONE
1/9
Piotroski Score
-2.4
Altman Z-Score
What Is Smart Money Doing with ENGN?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Grossman William | director officer | Buy | 5,102 | $10K | Sep 22, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ENGN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
56.85%
FCF Growth YoY
-104.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for ENGN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ENGN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:11:34 | $1.97 | 1,000 | $$2K | BUY |
| 15:11:31 | $1.97 | 2,500 | $$5K | BUY |
| 15:11:26 | $1.97 | 5,000 | $$10K | BUY |
| 15:11:26 | $1.96 | 2,000 | $$4K | SELL |
| 15:11:25 | $1.97 | 8,000 | $$16K | BUY |
5 dark pool trades shown · $$36K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ENGN
PREVIEWSEPT Investing provides real-time options flow tracking for ENGN, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $2 | Dec 18 | 36 | $$200 | 10 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for enGene Therapeutics Inc. (ENGN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ENGN — frequently asked questions
What is ENGN stock price today?
enGene Therapeutics Inc. (ENGN) is at $1.98, up 9.72% (+$0.18) at the Nov 12, 2026 close.
Why is ENGN stock moving today?
Latest ENGN news — Nov 12, 2026: enGene Reports New Pivotal Bladder Cancer Data and Names Executives · Nov 12, 2026: Piper Sandler raises enGene Therapeutics to Overweight, keeps $4 target
What is the ENGN price target?
The average analyst price target for ENGN is $4.00, ranging from $2 to $4, based on 3 analysts. Latest: HC Wainwright & Co. maintains on Jun 16, 2026.
What do analysts rate ENGN?
Analyst ratings for ENGN: 0 Buy, 3 Hold, 5 Sell — consensus Sell.
Did ENGN beat earnings?
ENGN last reported on Sep 8, 2026: EPS -$0.47 vs -$0.43 expected — a miss of 10.2%.
What is ENGN's P/E ratio?
ENGN trades at a P/E of 0.7.
Does ENGN pay a dividend?
ENGN does not currently pay a dividend.
What are ENGN support and resistance levels?
Support: $1.88, $1.75, $1.63. Resistance: $2.02, $6.05, $6.31.
What are insiders doing with ENGN?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on ENGN?
Nov 12, 2026: enGene Reports New Pivotal Bladder Cancer Data and Names Executives · Nov 12, 2026: Piper Sandler raises enGene Therapeutics to Overweight, keeps $4 target · Nov 12, 2026: Wells Fargo raises enGene Therapeutics to Overweight, price target to $6